TITLE

DSP and Nitto Denko initiate Phase II schizophrenia studies

PUB. DATE
September 2012
SOURCE
PharmaWatch: CNS;Sep2012, Vol. 11 Issue 9, p11
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the start of Phase II studies by Dainippon Sumitomo Pharma (DSP) and Nitto Denko Corp. for a transdermal patch formulation of the atypical antipsychotic Lonasen for the treatment of schizophrenia. Results of Phase I studies are mentioned. General characteristics of a transdermal patch formulation include ability to maintain a stable drug concentration in the blood and less susceptibility to dietary effects.
ACCESSION #
79660197

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics